nimotuzumab
biocon,oncoscience,daiichi sankyo
['nxcel1311', 'nimotuzumab']
nimotuzumab/crt for unresectable escc -nxcel1311 ph3 trial: orr 93% vs 72% no os data yet g3-5 aes 11.1% vs.10.9% no severe skin tox agreed that we buried efgr too early in escc lot to learn how select between egfr and/or io combined to crt #asco22
Brazilian Medical Oncologist, Advanced Fellow at GI Medical Oncology Service - MSKCC #gicancers